PCAC Briefing · Friday, July 24, 2026
Epitalon before the compounding committee
FDA proposes not adding either epitalon substance to the 503A Bulks List, citing inadequate characterisation, limited historical use, no evidence of effectiveness for insomnia, and an absence of safety data — including on whether it would cause harm in humans.
Published July 16, 2026 · By the Grey Peptides Editorial Board · ✓ Sourced from FDA's briefing document
| Substances | Epitalon (free base) and epitalon acetate |
| Also known as | Epithalon, AEDG, Ala-Glu-Asp-Gly |
| Length | 4 amino acids (Ala-Glu-Asp-Gly) |
| Use FDA reviewed | Insomnia |
| Forms proposed | Subcutaneous injection, per the nomination package |
| Nomination | Nominations withdrawn; FDA evaluated at its own discretion |
| FDA staff position | Proposes not adding either form to the 503A Bulks List |
What FDA reviewed it for
FDA evaluated epitalon for insomnia — not for the anti-ageing uses it is mostly marketed for.
This is not a detail to skip past. FDA evaluates a bulk drug substance in the context of the use proposed for it — so the question in front of the committee is not "is Epitalon useful?" but "does the evidence support compounding Epitalon for insomnia?" A substance can have an interesting research literature in a completely different area and still fail this test, because that literature was never the thing under review.
FDA's specific objections
FDA weighs four criteria: whether the substance is well characterised physically and chemically, whether it has been used historically in compounding, what evidence exists on effectiveness, and what safety issues its use in compounding raises. Here is where Epitalon landed on each.
FDA says neither form is well characterised, citing naming that does not follow established chemical nomenclature standards among other gaps.
FDA describes the information on historical use as limited — weaker than for most of the other six.
FDA concluded there is a lack of evidence to support effectiveness for insomnia, a condition it notes is associated with multiple serious adverse health outcomes and for which approved drugs with well-characterised safety profiles exist.
FDA says it lacks data to support the safety of these substances in humans, including whether they would cause harm when given subcutaneously, and did not identify information addressing immunogenicity risk.
What is specific to Epitalon
Six of the seven objections above could be written about almost any of the compounds on the July agenda. These next points could not — they are what makes this file different from the other six.
FDA's briefing describes epitalon being marketed online by wellness clinics and concierge practices as an anti-ageing agent — with websites calling it a fountain of youth, claiming it raises telomerase and thereby reverses ageing, extends lifespan and prevents cancer, heart disease and dementia. FDA reports these as claims made by those websites. They are not findings, and FDA did not evaluate epitalon for any of them.
FDA describes three studies of epitalon's effect on spontaneous malignant tumour incidence and lifespan in mice — similar designs, all from the same research group. It identified no additional studies assessing genotoxic potential, and no developmental or reproductive toxicity studies. For a compound promoted for indefinite anti-ageing use, the long-term data is three related mouse studies from one lab.
FDA notes an orphan drug designation for retinitis pigmentosa granted in September 2010 was withdrawn or revoked in January 2016. A designation is not an approval, and this one no longer stands.
The evidence picture
Grey Peptides grades epitalon's evidence base as low. The literature is largely Russian-language work centred on one research group, and the marketed anti-ageing claims are not supported by the kind of evidence a regulator weighs. Note that FDA spells it “epitalon”; this site's encyclopedia entry uses “Epithalon,” and both refer to the same tetrapeptide.
Two readings of the same file are worth separating. FDA's conclusion is about a regulatory question — whether the record supports letting pharmacists compound this substance for this use. That is a higher bar than "there is some interesting science here," and a lower bar than "this substance is harmful." Almost everything FDA said about Epitalon is a statement about missing information, not a finding of harm. Reporting that as "FDA says Epitalon is dangerous" is wrong. So is reporting it as "FDA found no safety problems."
Where this sits in our encyclopedia
Our entry on this compound covers the underlying pharmacology, the published literature, and the status picture independent of this meeting. The two are separate reads: the encyclopedia entry is about the compound, and this page is about the regulatory file.
Mechanism, evidence grade, half-life, approval status, and sources. PCAC July 2026 — the full picture
All seven compounds, what the vote does and doesn't change, and what to watch. Peptide Regulatory Status Tracker
Category 1/2/3, 503A vs 503B, and where every peptide sits.
The other six compounds
BPC-157 · KPV · TB-500 · MOTS-c · Emideltide (DSIP) · Semax
FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee ↗
FDA briefing documents released June 29, 2026. Federal Register notice 91 FR 20465, published April 16, 2026 (FR Doc. 2026-07361), Docket No. FDA-2025-N-6895. FDA Briefing Document for Epitalon (free base) and epitalon acetate, released June 29, 2026.